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 To the Editor, 
 Plasma total Hcy (tHcy) is the biochemical marker rou-
tinely evaluated and considered clinically useful. 
 Hyperhomocysteinaemia (HHcy) is a well-established 
independent risk factor for cardiovascular diseases; the 
role of homocysteinaemia in risk stratification was largely 
supported by epidemiological studies [1]. 
 Hyperhomocysteinaemia has recently also been asso-
ciated with other pathological conditions such as periph-
eral neuropathy, renal failure, hypotiroidism, Alzheimer 
disease and other dementias, pregnancy complications 
and birth defects [1, 2]. 
 Since homocysteine (Hcy) metabolism is catalysed 
by enzymes requiring B vitamins as cofactors, tHcy can 
also be considered a marker for folate and cobalamin defi-
ciency [3, 4]. 
 Thanks to the introduction of automated platform, 
tHcy concentration is more and more widely routinely 
measured as independent risk factor for cardiovascu-
lar diseases, or along with other metabolically-related 
markers. 
 We report the results of a study evaluating the analyti-
cal performance of the new immunoenzymatic assay ST 
AIA-Pack HomoCYS for measuring tHcy in human blood 
on AIA 600II Analyser (Tosoh Bioscience, Tokyo, Japan); 
the method was also compared with other commercial 
methods, namely Fluorescence Polarization ImmunoAs-
say (FPIA) Homocysteine assay on AxSYM (Abbott Diag-
nostics, Abbott Park, IL, USA), Chemiluminescent Micro-
particle ImmunoAssay (CMIA) Homocysteine assay on 
Architect i2000SR (Abbott Diagnostics), and Homocys-
teine liquid enzymatic assay (Sentinel Diagnostics, Milan, 
Italy) on Modular P analyser (Roche Diagnostics, Indian-
apolis, IN, USA). The aim was to evaluate whether this 
new method reaches the established analytical goals and 
can be considered suitable for routine testing. 
 The ST AIA-PACK HomoCYS is a competitive immu-
noenzymatic assay which after sample pre-treatment is 
performed entirely in the ST AIA-PACK HomoCYS cups. 
Sample Hcy competes with enzyme-labelled Hcy for a 
limited number of binding sites on homocysteine-specific 
antibody immobilised on magnetic beads. After incu-
bation, the beads are washed to remove the unbound 
enzyme-labelled homocysteine and then incubated with 
a fluorogenic substrate, 4-methylumbelliferyl phosphate. 
The amount of enzyme-labelled homocysteine that binds 
to the beads is inversely proportional to the homocysteine 
concentration in the test sample. A standard curve using 
a range of known standard concentrations (from 0 to 
55  µ mol/L) is constructed and unknown sample homo-
cysteine concentrations are calculated using this curve. 
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 Imprecision was determined by using the two levels ’ 
controls provided by the manufacturer and three differ-
ent patient-pools measured 20 times in the same run (for 
intra-assay imprecision) and in duplicate in every single 
run during 20 days (for inter-assay imprecision). 
 Intra- and inter-assay imprecision were expressed as 
coefficient of variation (CV) %. 
 The limit of detection (LoD) was determined accord-
ing to CLSI EP 17A2 document [5]. 
 Recovery was assessed by using a plasma sample 
with known high tHcy concentration (37.7  µ mol/L) spiked 
at a ratio of 1:10 with five plasma samples with known low 
tHcy concentrations (range 6.7 – 8.2  µ mol/L); all samples 
were tested before and after spiking, and the recovery was 
calculated as the percentage of obtained/expected. 
 Linearity test was performed by diluting five patients ’ 
samples (concentration near 40  µ mol/L) with AIA-PACK 
HomoCYS sample diluent in order to obtain serial dilu-
tions (up to 1:32); all samples were processed in duplicate 
and the resulting percent recovery was calculated. 
 Method comparison was assessed on EDTA plasma 
samples obtained from 243 subjects coming to our labo-
ratory for tHcy routine determination with Homocysteine 
liquid enzymatic assay (Sentinel Diagnostics) on Modular 
P analyser (Roche Diagnostics). Plasma aliquots were 
stored at  − 80 ° C unless analysed the day of collection. 
In particular, out of the 243 samples, 143 were also used 
for method comparison with AxSYM (Abbott), and 85 for 
method comparison with Architect (Abbott). 
 All statistical analysis were performed on software 
MedCalc [6]. 
 As shown in  Table 1 total analytical imprecision for 
the AIA-PACK HomoCYS was 6.2% for controls and 6.05% 
for plasma pools. Mean recovery and mean dilution 
recovery were 103.9% (range 100.4% – 107.2%) and 102.5% 
(range 96.6% – 110%), respectively; linearity test showed 
optimum results at dilutions up to 1:16 (mean r = 0.94) and 
good results up to 1:32 (mean r = 0.91). The LoD for AIA-
PACK HomoCYS was 0.15  µ mol/L. 
 tHcy concentrations measured in 243 plasma samples 
in parallel on AIA 600II and Modular P ranged from 
4.6 to 46.8  µ mol/L and from 3.8 to 50.0  µ mol/L, respec-
tively; tHcy values obtained in 143 samples on AxSYM 
and in 85 samples on Architect were 4.0 – 45.3  µ mol/L and 
4.0 – 37.6  µ mol/L, respectively. 
 AIA-PACK HomoCyS compared well with all the three 
methods evaluated as shown in  Table 2 ; results of the 
Passing and Bablok and Deming regression analyses were 
nearly equivalent. 
 The agreement of tHcy measurements, obtained with 
AIA-PACK HomoCYS Tosoh and with each of the other 
methods, was analysed with the Bland and Altman plots 
showing mean difference of  − 0.8  µ mol/L (95% CI  − 3.5 and 
 + 2.0  µ mol/L),  − 0.3  µ mol/L (95% CI  − 3.0 and  + 2.4  µ mol/L) 
and  − 0.5  µ mol/L (95% CI  − 3.1 and  + 2.0  µ mol/L) with 
 Modular-P, AxSYM and Architect, respectively. 
 The reference method for determining tHcy is liquid 
chromatography [2, 7], but it is generally unsuitable for 
large routine. During recent years several methods have 
been developed and proposed on automated analysers, 
due to the increasing need of Hcy evaluation in a variety 
of physiopathologic conditions [2]. 
 The physiopathological interval (0.5th – 99.5th percen-
tiles of the general population) for tHcy concentration is 
approximately 3 – 40  µ mol/L [2] and it fits in the analytical 
range of the immunoenzymatic method evaluated. 
 Total analytical imprecision was  < 7%; in particu-
lar total CV% was  < 6% for tHcy concentrations near 
15  µ mol/L, the critical level corresponding to the upper 
reference limit. 
 Table 1   Imprecision of AIA-PACK HomoCyS from controls and plasma pools. 
 
 
 
 
 Total homocysteine concentration  Imprecision, 
 CV%  Target value,  µ mol/L  Mean ± SD,  µ mol/L 
 Intra-assay  Control 1 (n = 20)  15.8  16.83 ± 0.83  4.9 
  Control 2 (n = 20)  27.3  29.54 ± 2.20  7.5 
  Pool 1 (n = 20)  NA  19.18 ± 1.00  5.2 
  Pool 2 (n = 20)  NA  23.35 ± 1.24  5.3 
  Pool 3 (n = 20)  NA  20.12 ± 0.76  3.8 
 Inter-assay  Control 1 (n = 20)  15.8  16.47 ± 0.97  5.9 
  Control 2 (n = 20)  27.3  28.23 ± 1.85  6.5 
  Pool 1 (n = 20)  NA  18.63 ± 1.04  5.6 
  Pool 2 (n = 20)  NA  23.12 ± 1.88  8.1 
  Pool 3 (n = 20)  NA  19.51 ± 1.60  8.2 
 CV, coefficient of variation; NA, not applicable; SD, standard deviation. 
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 Table 2   Correlation of AIA-PACK HomoCyS (Tosoh) with FPIA Homocysteine assay on AxSYM (Abbott), CMIA Homocysteine assay on Archi-
tect i2000SR (Abbott), and Homocysteine liquid enzymatic assay Sentinel on Modular P (Roche). 
 Assay comparison 
 
 Tosoh/Sentinel-Roche 
 n = 243 
 Tosoh/AxSYM 
 n = 143 
 Tosoh/Architect 
 n = 85 
 Deming regression    
  Slope (95% CI)  0.9238 (0.8953 0.9522)  0.9701 (0.9321 1.0081)  0.9865 (0.9329 1.0402) 
  Intercept (95% CI)  1.9069 (1.5413 2.2725)  0.7376 (0.2071 1.2681)  0.7469 (0.0229 1.4709) 
 Passing and Bablok    
  Slope (95% CI)  0.9767 (0.9492 1.0000)  0.9924 (0.9630 1.0185)  1.0028 (0.9639 1.0396) 
  Intercept (95% CI)  1.1953 (0.9000 1.4881)  0.2950 ( − 0.0598 0.69637)  0.3681 ( − 0.1579 0.8880) 
 Spearman ’ s rank correlation  0.983  0.979  0.979 
  (p < 0.0001)  (p < 0.0001)  (p < 0.0001) 
 Refsum et  al. recommended a total imprecision for 
tHcy assays  < 5%, nevertheless imprecision determined 
for the ST AIA-Pack HomoCYS should be considered 
acceptable. 
 The ST AIA-Pack HomoCYS on Tosoh AIA 600II Ana-
lyser demonstrated good overall comparability with the 
other three immunoassays considered and routinely 
used in clinical biochemistry laboratories. Both Deming 
regression and Passing and Bablok test showed slope 
values near 1.00 and positive y-intercepts ranging from 
0.2950 (Tosoh vs. AxSYM) to 1.9069 (Tosoh vs. Sentinel-
Roche). The Bland-Altman plots highlighted a good 
agreement of ST AIA-Pack HomoCYS and the other immu-
noassays with  < 7% of values differing by 2 SD, and on 
average a little overestimate in comparison to all the 
other methods, with no remarkable difference in wide-
ness of bias depending on tHcy concentration. 
 In conclusion, considering the acceptable performance 
and the good agreement with other routine methods, 
together with the analytical characteristics of AIA 600II 
Analyser (low reagent/consumable cost, number results/
hour, user friendly, fully automated), ST AIA-Pack HomoCYS 
can be considered suitable for routine use, evaluated alone 
or as a part of the metabolic panel together with the related 
vitamin. 
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